Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
566.1 USD | -0.33% | -8.39% | -3.19% |
Apr. 26 | Chemed Reports 'Soft' Q1 as Roto-Rooter Continues to Face Pressure, Oppenheimer Says | MT |
Apr. 25 | Transcript : Chemed Corporation, Q1 2024 Earnings Call, Apr 25, 2024 |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2024 P/E ratio at 27.13 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.19% | 8.57B | C+ | ||
-28.69% | 85.35B | B- | ||
+14.32% | 81.95B | C+ | ||
+9.37% | 28.99B | C+ | ||
-11.43% | 16.98B | B | ||
-0.36% | 16.85B | A- | ||
-0.24% | 15.35B | A- | ||
+4.32% | 12.42B | A- | ||
+33.40% | 12.19B | B- | ||
-31.40% | 11.89B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CHE Stock
- Ratings Chemed Corporation